Multivariable regression analysis for EFS, OS, and RR
| . | EFS . | OS . | Relapse risk end course 1 . | |||||
|---|---|---|---|---|---|---|---|---|
| n . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | n . | HR (95% CI) . | P value . | |
| ITDFR | 118 | 1 | 1 | 105 | 1 | |||
| ITDINT | 134 | 1.91 (1.30-2.78) | .001 | 2.07 (1.3-3.31) | .002 | 92 | 1.74 (1.07-2.84) | .027 |
| ITDPR | 202 | 3.70 (2.61-5.24) | <.001 | 3.48 (2.26-5.37) | <.001 | 95 | 3.87 (2.44-6.14) | <.001 |
| LAR | 166 | 1 | 1 | 112 | 1 | |||
| HAR | 288 | 1.25 (0.83-1.45) | .097 | 1.29 (0.94-1.76) | .117 | 180 | 1.17 (0.79-1.73) | .431 |
| Chemotherapy treatment | 256 | 1 | 1 | 160 | 1 | |||
| Gemtuzumab ozogamicin treatment | 110 | 1.10 (0.83-1.45) | .526 | 1.06 (0.77-1.47) | .723 | 70 | 0.69 (0.44-1.10) | .118 |
| Sorafenib + HCT in CR1 (arm C AAML1031) | 88 | 0.63 (0.43-0.93) | .019 | 0.81 (0.52-1.26) | .355 | 62 | 0.30 (0.15-0.61) | .001 |
| HCT in CR not received | 291 | 1 | 1 | 163 | 1 | |||
| HCT in CR received (TVC) | 163 | 0.60 (0.43-0.83) | .002 | 0.62 (0.44-0.87) | .006 | 129 | 0.57 (0.37-0.90) | .016 |
| . | EFS . | OS . | Relapse risk end course 1 . | |||||
|---|---|---|---|---|---|---|---|---|
| n . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | n . | HR (95% CI) . | P value . | |
| ITDFR | 118 | 1 | 1 | 105 | 1 | |||
| ITDINT | 134 | 1.91 (1.30-2.78) | .001 | 2.07 (1.3-3.31) | .002 | 92 | 1.74 (1.07-2.84) | .027 |
| ITDPR | 202 | 3.70 (2.61-5.24) | <.001 | 3.48 (2.26-5.37) | <.001 | 95 | 3.87 (2.44-6.14) | <.001 |
| LAR | 166 | 1 | 1 | 112 | 1 | |||
| HAR | 288 | 1.25 (0.83-1.45) | .097 | 1.29 (0.94-1.76) | .117 | 180 | 1.17 (0.79-1.73) | .431 |
| Chemotherapy treatment | 256 | 1 | 1 | 160 | 1 | |||
| Gemtuzumab ozogamicin treatment | 110 | 1.10 (0.83-1.45) | .526 | 1.06 (0.77-1.47) | .723 | 70 | 0.69 (0.44-1.10) | .118 |
| Sorafenib + HCT in CR1 (arm C AAML1031) | 88 | 0.63 (0.43-0.93) | .019 | 0.81 (0.52-1.26) | .355 | 62 | 0.30 (0.15-0.61) | .001 |
| HCT in CR not received | 291 | 1 | 1 | 163 | 1 | |||
| HCT in CR received (TVC) | 163 | 0.60 (0.43-0.83) | .002 | 0.62 (0.44-0.87) | .006 | 129 | 0.57 (0.37-0.90) | .016 |
Multivariable regression analysis for EFS, OS, and RR according to cooccurring risk mutation group (FR, INT, PR), LAR (≤0.4) vs HAR (>0.4), treatment received, and HCT in CR as TVC.
Patients in the chemotherapy treatment group included patients on CCG2961, AAML0531 arm A, and AAML1031 arm A/B, patients in the gemtuzumab ozogamicin treatment group included patients treated on AAML03P1 and AAML0531 arm B, and patients in the sorafenib + HCT in CR1 group were those on AAML1031 arm C.
HR, hazard ratio; TVC, time-varying covariate.